76/100 B+ · Critical risk
1 serious risk flag found Indicative TraceComp estimate from public sources — an automated indicator, not a credit decision, a completed due-diligence check, or a guarantee. Verify against the official register.
  • 🔴 Insolvency / collective proceedings on file (3)

Think this is wrong? This is an automated estimate — request a human review or correction.

PHARMALEADS

Active Public limited company (SA) Scientific research & development Active for 25 years

Public limited company (SA) · RC 434136891 · Active since 2000

B+

Overview

PHARMALEADS is a public limited company (sa) registered in France, since 2000. The company operates in the scientific research & development sector. Its TraceComp score of 76 (B+) indicates solid fundamentals and low apparent risk. With 25 years of operations, the company has an established track record in its market.

Company Information

Registration Number
434136891
Legal Form
Public limited company (SA)
Registered
2000-12-01

Financial Profile

Latest filed accounts: FY 2024

Revenue (2024) 0 EUR
Net Income -179,362 EUR
Total Assets 1,130,462 EUR
Altman Z -1.67 distress

Multi-year financials & ratios

5 years of filed accounts on file — full balance sheets, current ratio, debt-to-equity, net margin and the Altman-Z distress trend.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Officers & Management

8 officers/directors on file — names, roles, appointment & resignation dates.

NameRoleStatus
B•••••• R••••• Officer Current
T•••••• B•••••• Chief executive (directeur général) Current
P••••• W••••• Officer Current
+ 5 more in the full report

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Insolvency & Collective Proceedings

3 insolvency / collective-proceedings notices on file — most recent published 2025-10-22. A material adverse finding for counterparty and credit risk.

Insolvency notice types, titles, publication dates and official Gazette sources.

What’s in the full report

  • Financial statements — revenue, assets, equity & margins for every year on file (multi-year trend where available)
  • Key ratios & credit score — liquidity, leverage & profitability ratios plus our 0–100 score with a factor-by-factor breakdown
  • Insolvency & legal events — collective proceedings and adverse filings (where on record)
  • Charges & secured lending — registered charges and the creditors entitled (where filed)
  • Sanctions & screening — company-level watchlist & adverse signals
  • Sector benchmark & peers — how the company compares to its sector and nearest peers
  • Innovation & EU funding — patents, research output & EU research funding received (where applicable)
Instant access · 30-day access · no subscription · official public-register data only See a sample report → · Digital report delivered on payment; the 14-day withdrawal right is waived once opened (see Terms).

Research Output

Active research organization. 107 publications · 12,160 citations · h-index 67 in the global scholarly record (OpenAlex — 82.9M papers). Top fields by publication volume: Neuroscience (40%) · Medicine (35%) · Biochemistry, Genetics and Molecular Biology (25%).

See full research profile — top researchers & publications →

Source: OpenAlex (CC0). Objective publication & citation counts.

Patent Portfolio

Active patent holder. 11 patents · 10 active · 11 granted in the USPTO/EPO record.

See full patent portfolio — most-cited inventions & inventors →

Source: USPTO / EPO open patent data. Objective bibliographic counts.

Risk Signals

No adverse legal events have been recorded for this company.

  • Revenue down 100% year-on-year
  • Net loss reported in FY 2024
  • Altman Z-Score in the distress zone — elevated insolvency risk on the model

Data Sources & Freshness

Data sourced from: bulk register.